|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
7
|
|
pubmed:dateCreated |
1997-4-22
|
|
pubmed:abstractText |
Among high-grade malignant non-Hodgkin's lymphomas the updated Kiel classification identifies three major B-cell entities: centroblastic (CB), B-immunoblastic (B-IB), and B-large cell anaplastic (Ki-1+) (now termed anaplastic large cell [CD30+], [B-ALC]). The clinical prognostic relevance of this distinction was evaluated in a randomized prospective treatment trial (COP-BLAM/IMVP-16 regimen randomly combined +/- radiotherapy in complete responders) conducted in adult (age 15 to 75) patients with Ann Arbor stage II-IV disease (n = 219) diagnosed by optimal histomorphology (Giemsa staining) and by immunohistochemistry. Overall survival was significantly better in CB lymphoma as compared to B-IB (P = .0002) or B-ALC (P = .046). Relapse-free survival was worse for B-IB (P = .0003) as compared to CB lymphomas. The prognostic differences between CB and B-IB were confirmed by multivariate analyses including the risk factors of the International Index. Overall survival was significantly determined by performance status (P = .0003), serum-LDH (P = .036), and B-IB histology subtype (P = .036). Relapse-free survival was influenced by age (P = .007) and histological subtype (P = .007). Thus, the diagnosis of the CB and B-IB lymphomas by the histological criteria of the Kiel classification was identified as an independent prognostic factor in diffuse large B-cell lymphomas.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Apr
|
|
pubmed:issn |
0006-4971
|
|
pubmed:author |
pubmed-author:AydemirUU,
pubmed-author:BierwolfSS,
pubmed-author:BrittingerGG,
pubmed-author:EngelhardMM,
pubmed-author:GerhartzH HHH,
pubmed-author:GriesserHH,
pubmed-author:HuhnDD,
pubmed-author:LennertKK,
pubmed-author:MeusersPP,
pubmed-author:SiegertWW,
pubmed-author:ThielEE,
pubmed-author:TiemannMM,
pubmed-author:WilmannsWW
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
1
|
|
pubmed:volume |
89
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2291-7
|
|
pubmed:dateRevised |
2007-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:9116271-Adolescent,
pubmed-meshheading:9116271-Adult,
pubmed-meshheading:9116271-Age Factors,
pubmed-meshheading:9116271-Aged,
pubmed-meshheading:9116271-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:9116271-Bleomycin,
pubmed-meshheading:9116271-Combined Modality Therapy,
pubmed-meshheading:9116271-Cyclophosphamide,
pubmed-meshheading:9116271-Disease-Free Survival,
pubmed-meshheading:9116271-Doxorubicin,
pubmed-meshheading:9116271-Etoposide,
pubmed-meshheading:9116271-Female,
pubmed-meshheading:9116271-Humans,
pubmed-meshheading:9116271-Ifosfamide,
pubmed-meshheading:9116271-Life Tables,
pubmed-meshheading:9116271-Lymphoma, Large B-Cell, Diffuse,
pubmed-meshheading:9116271-Lymphoma, Large-Cell, Anaplastic,
pubmed-meshheading:9116271-Lymphoma, Large-Cell, Immunoblastic,
pubmed-meshheading:9116271-Male,
pubmed-meshheading:9116271-Methotrexate,
pubmed-meshheading:9116271-Middle Aged,
pubmed-meshheading:9116271-Multivariate Analysis,
pubmed-meshheading:9116271-Prednisone,
pubmed-meshheading:9116271-Procarbazine,
pubmed-meshheading:9116271-Prognosis,
pubmed-meshheading:9116271-Prospective Studies,
pubmed-meshheading:9116271-Radiotherapy, Adjuvant,
pubmed-meshheading:9116271-Risk Factors,
pubmed-meshheading:9116271-Survival Analysis,
pubmed-meshheading:9116271-Treatment Outcome,
pubmed-meshheading:9116271-Vincristine
|
|
pubmed:year |
1997
|
|
pubmed:articleTitle |
Subclassification of diffuse large B-cell lymphomas according to the Kiel classification: distinction of centroblastic and immunoblastic lymphomas is a significant prognostic risk factor.
|
|
pubmed:affiliation |
Department of Medicine, Hematology, Universitätsklinikum Essen, Germany.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Comparative Study,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't
|
